Malignancies in the multicenter AIDS cohort study (MACS), 1984-1994 (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Malignancies in the multicenter AIDS cohort study (MACS), 1984-1994 (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 15:A852 1996. Unique Identifier : AIDSLINE ICDB/97635852
Lyter DW; Kingsley LA; Rinaldo CR; Bryant J; Illinois Masonic Cancer Center, Chicago, IL 60657

Abstract: Since April 1, 1984, 5579 gay men have been followed by the MACS, a prospective study of the natural history of human immunodeficiency virus (HIV) infection. The cohort includes 2896 HIV seronegative (SN) participants and 2683 who were seropositive (SP) at enrollment or who seroconverted during the course of the study. Malignancy incidence data for the first 10.5 years of the study were collected via semi-annual visits, medical records, tumor registry information, telephone interviews and death certificates. 26,225 person-years and 17,780 person-years were contributed by the SN and SP cohorts, respectively. Kaposi's sarcoma (KS) was diagnosed in 473 (17.6%) of the SP men and in only one SN. Non-Hodgkin's lymphoma (NHL) occurred in 142 (5.3%) SP and in only one SN men. In addition, 88 (51 in SP and 37 in SN) non-AIDS defining malignancies (NADM) were detected (data presented in a table). Age-adjusted rates for each malignancy were calculated for both groups. These were compared against each other and against rates for the general male population found in the surveillance, epidemiology, and end results (SEER) program, using a standardized incidence rate (SIR) analysis. In addition to the expected increases in KS (SIR=456) and NHL (SIR=84), the combined rate of all NADM (SIR=2.6) was significantly elevated (p less than 0.05) in the SP cohort in comparison to the SN and SEER data. This increase was secondary to significant increases in rates of Hodgkin's disease (SIR=6.7), carcinoma of the anus (SIR=70.9), oropharyngeal malignancy (SIR=3.9) and testicular carcinoma (SIR=3.9), melanoma (SIR=2.9) and plasma cell myeloma (SIR=14.2). There were no differences in any cancer rate between the SN and SEER cohorts.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Cohort Studies Human Male Neoplasms/*COMPLICATIONS Registries ABSTRACT MEETING REPORTKWDacquiredimmunodeficiencysyndrome/KWDcomplicationscohortstudieshumanmaleneoplasms/KWDcomplicationsregistriesabstractmeetingreport
970330
M9731533

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .